Skip to content

    Breast Cancer Health Center

    Font Size

    'Magic Bullet' Drug Delays Breast Cancer Worsening

    T-DM1 Spares Women From Some, But Not All, Serious Side Effects
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    June 4, 2012 (Chicago) -- A new targeted cancer drug delayed the worsening of metastatic breast cancer, possibly with fewer side effects than traditional treatments, according to results of a late-stage study.

    Called T-DM1, the new drug combines Herceptin with a potent chemotherapy drug. It's been called a "magic bullet": Herceptin homes in on cancer cells and delivers the cancer-killing agent directly to its target without damaging nearby cells.

    The study involved nearly 1,000 women with metastatic breast cancer that was continuing to get worse despite treatment with Herceptin and a common chemotherapy drug.

    Half the women got T-DM1 and the other half got Tykerb and Xeloda, a standard treatment for women who aren't helped by Herceptin.

    T-DM1 delayed the time to the disease progressing by about three months. Among women who received T-DM1, the average time before the disease got worse was about nine-and-a-half months vs. about six-and-a-half months for those getting the standard drugs.

    Although a few months might not sound like much, it can be a huge gain for seriously ill patients who are running out of options, say doctors studying the drug.

    It is still too early to know for sure that T-DM1 will prolong lives, but the early data suggest that it will, says researcher Kimberly Blackwell, MD, of Duke University.

    For the most part, women taking T-DM1 did not suffer the often debilitating side effects associated with chemotherapy, such as diarrhea, nausea, vomiting, and hair loss, she tells WebMD.

    Still, the drug is not without toxicity: About 41% of women on T-DM1 suffered a serious side effect vs. 57% of those getting standard treatment.

    About 13% of women getting T-DM1 had lowered blood platelet counts, which can increase the risk of bleeding. But there were very few cases of bleeding.

    The findings were presented here at the annual meeting of the American Society of Clinical Oncology.

    How T-DM1 Works

    About 20% of breast cancer patients have an aggressive form of the disease known as HER2-positive tumors. Herceptin, a man-made antibody, binds to and blocks part of the HER2 protein that appears on the surface of some breast cancer cells. It revolutionized the way this type of tumor was treated when it was approved in the late 1990s.

    Today on WebMD

    Breast Cancer Overview
    From mammograms to living after treatment.
    Dealing with breast cancer
    Get answers to your questions.
    woman having mammogram
    The 3 latest tips to know.
    woman undergoing breast cancer test
    Most abnormalities aren’t breast cancer.
    Resolved To Quit Smoking
    Breast Cancer Treatments Improving
    Woman getting mammogram
    Screening Tests for Women
    serious woman
    Pink badge on woman chest to support breat cancer
    what is your cancer risk
    breast cancer survivors